

Foralumab

Cat. No.:	HY-P99199
CAS No.:	946415-64-1
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells ^[1] .	
IC ₅₀ & Target	Target: CD3	
In Vivo	Foralumab (NI-0401; 0.6-250 µg; p.o.; daily, for 5 d) delays the rejection of B6Rag2 ^{-/-} skin grafted onto the humanized mice ^[1] .	
	Foralumab (0.6-250 µg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems ^[1] .	
	Foralumab (1-15 µg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice ^[1] .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Humanized NOD/SCID IL-2γc ^{-/-} mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) ^[1]
	Dosage:	15 µg
	Administration:	Oral administration; daily, for 5 days and weekly dosing
	Result:	Showed robust protection against graft rejection and prolongs graft survival. Reduced proliferation of CD8+ T cells and reduced release of TNF. Increased the concentration of IL-10.
	Animal Model:	Humanized NOD/SCID IL-2γc ^{-/-} mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) ^[1]
	Dosage:	1, 5, 15, 50, and 250 µg (p.o.), 0.6 mg/kg (i.h.)
	Administration:	Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
	Result:	Had tolerant to autologous skin grafts in humanized mice.
	Animal Model:	Humanized NOD/SCID IL-2γc ^{-/-} mice with Skin grafts (Humanized mice: CD34+ cells are

	injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) ^[1]
Dosage:	0, 5, 10, and 15 µg
Administration:	Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing
Result:	Increased human Ig on the surface of CD4+ and CD8+ T cells. Had free mAb in the serum of mice

REFERENCES

[1]. Ogura M, et, al. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Immunol. 2017 Oct;183:240-246.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA